We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GAO: Less than Half of Companies Know Source of Conflict Minerals

GAO: Less than Half of Companies Know Source of Conflict Minerals

August 21, 2015

A new Government Accountability Office report has found that most companies don’t know the origin of their so-called conflict minerals — tantalum, tin, tungsten and gold — meaning they could be acquiring them from countries rife with humanitarian abuses.

According to a sampling of firm filings examined by the GAO, 94 percent of companies report doing their due diligence in tracking the chain of custody of conflict minerals. However, 67 percent could not determine whether the minerals came from the Democratic Republic of Congo, or neighboring countries that fund armed insurgents that practice human rights abuses within the DRC.

Devicemakers are among those that have had trouble sourcing these minerals. In filings covering 2013, both Medtronic and Integra LifeSciences confirmed they could not identify the country of origin. Both said the complexity of the supply chain makes doing so difficult.

The report comes as part of the 2010 Dodd-Frank Wall Street Reform and Consumer Protection Act, which requires the Securities & Exchange Commission to collect data on companies’ use of these minerals from the DRC, Central African Republic, South Sudan, Zambia and Angola. Only 1,321 companies filed the forms, far fewer than the SEC estimate of 6,000 that could be affected by the rule.

Even as the SEC collects this information, the U.S. Court of Appeals for the D.C. Circuit ruled Aug. 18 that forcing companies to state on their websites that products have “not been found to be ‘DRC conflict free’” violates the First Amendment, covering corporate speech. The ruling puts the future of the rule in doubt.

In May, European lawmakers voted 402 to 118, with 171 abstentions, to require devicemakers that use conflict minerals to certify that the minerals aren’t sourced from certain zones (IDDM, May 22). Parliament also voted to enter into talks with member states to agree on a final version. No date has been set for final adoption.

To read the GAO report, visit www.fdanews.com/082415-SEC-minerals.pdf. The appeal court ruling is at www.fdanews.com/082415-decision.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing